Gene Editing Restores Factor VIII Levels, Eases Bleeding in Mice with Hemophilia A
Combining two gene editing approaches in cells derived from a patient with severe hemophilia A successfully restored the levels…
Articles by José Lopes, PhD
Longer-lasting Jivi Improves Health and Life Quality, Men with Severe Hemophilia A Say
Less frequent infusions with Jivi led to fewer bleedings, a greater ability to engage in physical and workplace activities, less…
Limited Access to Hemophilia Treatment and Expert Care in Developing Countries Reasons Joint Damage Seen, Study Reports
Inadequate access to treatment centers, lack of expert care, and high bleeding rates lead to similar joint complications in…
Ratio Between FVIII and Von Willebrand Factor Predicts Relapse in Patients with Acquired Hemophilia A, Study Reveals
The ratio between the blood clotting protein factor VIII (FVIII) and the von Willebrand factor (VWF) may be a reliable…
Improved Care May Explain the Higher Prevalence of Male Hemophiliacs in Indiana, Study Reports
Fewer HIV infections and better care may explain the higher prevalence of hemophilia in male patients in Indiana between…
Healthcare Costs Higher with Bypassing Agents than Factor Replacement Therapy in Hemophilia A, Study Reports
Treatment of hemophilia A with bypassing agents is associated with significantly higher costs than with factor replacement…
Prophylaxis Partially Prevents Bleeding in Severe Hemophilia A Patients, Real‐world Study Finds
Regular preventive treatment is able to at least partially prevent bleeding episodes in adolescent and adult males with severe…
First Patient Treated in Phase 3 Trial of AMT-061 in Hemophilia B
A Phase 3 clinical trial of treatment candidate AMT-061 for severe and moderately severe hemophilia B has treated its first…
Activities and Levels of Bleeding Risk They May Carry Ranked by Physical Therapists
Repetitive movements, fitness level, and prolonged and competitive physical activity are among the factors that raise bleeding risks for people…
Eloctate and Alprolix Show Long-Term Effectiveness for Hemophilia in Extension Studies
Treatment of severe hemophilia A with Eloctate and hemophilia B with Alprolix was safe and improved the patients’ annualized bleed…